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OBJECTIVES We evaluated C-reactive protein (CRP) and troponin T (TnT) for predicting six-month
cardiac risk in patients with unstable angina.
BACKGROUND Troponin T is predictive of cardiac risk in patients with unstable angina. The clinical
implications of elevated CRP in such patients remains controversial.
METHODS Baseline TnT and CRP values were determined in 447 patients with unstable angina enrolled
in the placebo group of the Chimeric c7E3 AntiPlatelet Therapy in Unstable angina
REfractory to standard treatment trial (CAPTURE) trial. All patients underwent a coronary
intervention and were followed for a six month period in which 13 deaths and 47 myocardial
infarctions were documented (MIs).
RESULTS Troponin T was .0.1 mg/liter in 30% and CRP was .10 mg/L in 41% of the patients. For
the initial 72-h period (including coronary intervention), TnT (17.4% vs. 4.2%; p , 0.001)
but not CRP (10.3% vs. 8%; p 5 0.41) was predictive of mortality and MI. The TnT-positive
patients displayed more frequent recurrent instability before the planned intervention (44.8%
vs. 16.9%; p , 0.001), but in the CRP-positive patients, no such increase was observed
(25.9% vs. 24.8%; p 5 0.92). In contrast, for the six month follow-up period, CRP was
predictive of cardiac risk (mortality, MI) (18.9% vs. 9.5%; p 5 0.003). Using multivariate
analysis, both CRP and TnT emerged as independent predictors of mortality and MI at six-
month follow-up. Furthermore, the incidence of coronary restenosis during six-month
follow-up was not related to TnT status (3% vs. 4.5%; p 5 0.49); however, it was significantly
related to CRP status (7% vs. 2.3%; p 5 0.03).
CONCLUSIONS Troponin T, but not CRP, was predictive of cardiac risk during the initial 72-h period,
whereas CRP was an independent predictor of both cardiac risk and repeated coronary
revascularization (coronary artery bypass graft surgery and percutaneous transluminal
coronary angioplasty) during six month follow-up. (J Am Coll Cardiol 2000;35:
1535– 42) © 2000 by the American College of Cardiology
For patients with unstable coronary artery disease (i.e.,
unstable angina or non–Q wave myocardial infarction
[MI]), the main pathophysiologic mechanisms, in the form
of plaque rupture or erosion, are followed by exposure of
thrombogenic contents, such as collagen, to the circulation
(1,2). The resulting platelet activation and adhesion pro-
mote thrombus formation. Pathohistologic studies have
disclosed focal cell necroses distal in the myocardium
supplied by the culprit artery, which have been attributed to
repetitive embolization from such friable thrombi (3,4). The
resulting minor myocardial damage leads to troponin T
(TnT) release in about one-third of such patients (5–13).
Although enzyme activity of creatine kinase (CK) remains
within the normal range, there is a five- to 10-fold higher
incidence for mortality and MI during the 30-day follow-up
period for such TnT-positive patients (5,6,13).
There is growing evidence that local and systemic inflam-
mation plays a role in the initiation and progression of
atherosclerosis (14,15); patients with unstable angina had
higher plasma levels of C-reactive protein (CRP) than did
patients with stable angina (16,17). Such inflammatory
reactions may promote plaque fissuring or erosion and may
be involved in the onset of an acute coronary syndrome.
However, the clinical implications of elevated CRP levels
for improved early risk stratification of such patients remain
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controversial (14,18–22). To shed light on the clinical
significance of elevated CRP levels, we performed a com-
parative analysis of the predictive values of both CRP and
TnT for patients with unstable angina by using the data set
of the Chimeric c7E3 AntiPlatelet Therapy in Unstable
angina REfractory to standard treatment (CAPTURE) trial
(23). The CAPTURE trial was designed to assess outcomes
in patients with refractory unstable angina who were given
either abciximab or placebo up to 24 h before scheduled
percutaneous transluminal coronary angioplasty (PTCA).
METHODS
Patients. The CAPTURE trial enrolled 1,265 patients
with refractory unstable angina (61% men, 61 6 10 years
old) between May 1993 and December 1995. All CAP-
TURE patients had recurrent chest pain at rest associated
with electrocardiographic (ECG) changes during treatment
with intravenous heparin and glyceryl trinitrate for an
average of 14 h. This entire group had coronary angiography
before randomization, indicating significant coronary artery
disease with a culprit lesion of $70% diameter stenosis
suitable for angioplasty. The patients were randomly as-
signed to abciximab or placebo; treatment was initiated
within 2 h of randomization. For all patients, coronary
interventions were scheduled between 18 and 24 h after
beginning study treatment (23).
The primary end points of our study were mortality, MI
or the necessity for an urgent intervention (PTCA or
coronary artery bypass graft surgery [CABG]) due to
instability during the 30-day and six-month follow-up
periods. Patients with MI during the index hospital stay
were defined as having values of CK enzyme activity more
than three times the upper limit of normal in at least two
samples or an ECG with new significant Q waves in two or
more contiguous leads. This strict definition was chosen to
exclude any insignificant minor CK rise after PTCA.
Patients with an MI after hospital discharge were defined as
having values of CK enzyme activity more than two times
the upper limit of normal or an ECG with new significant
Q waves in two or more contiguous leads. The secondary
end point was symptomatic coronary restenosis of the
treated lesion with $70% diameter stenosis and the neces-
sity for repeat revascularization during the six-month
follow-up period.
Four time periods were considered for this study: 1) up to
24 h before PTCA; 2) up to 72 h after randomization
(including coronary intervention); 3) 30-day follow-up pe-
riod; and 4) 6-month follow-up period.
Analytic techniques. Determination of the cardiac mark-
ers in serum samples obtained at baseline (n 5 1,096; mean
8.7 h [75% confidence interval 3.6 to 11.3] after the onset of
symptoms) and before discharge (n 5 918) was performed
without knowledge of the patients’ histories and allocated
treatment. For quantification of TnT, a one-step enzyme
immunoassay based on electrochemiluminescence technol-
ogy (Elecsys 2010, Boehringer Mannheim, Germany) was
used. The lower detection limit of this assay was
0.01 mg/liter, and the diagnostic threshold level was 0.10
mg/liter (24,25). C-reactive protein was measured by N
Latex CRP Mono tests, performed on a Behring BN II
Nephelometer (Behring Diagnostics) using polystyrene mi-
crobeads coated with monoclonal mouse antibodies (26).
The intensity of scattered light due to formed aggregates
was proportional to the CRP level present in the sample.
The detection limit of the assay was 0.2 mg/liter. For
clinical practice, a threshold level of 5.0 mg/liter is recom-
mended.
Statistical methods. After blind assessment of CRP and
TnT, the test results were merged with the CAPTURE
data base. Continuous variables are expressed as the mean
value 6 SD, with analysis of subgroups by the Mann-
Whitney U test (two-sided). Categoric variables were com-
pared using the Fisher’s exact test. Significance was set at
p , 0.05.
To distinguish between patients with different degrees of
cardiac risk, an exploratory data analysis was chosen. Pa-
tients were categorized according to the CRP concentration
of quintiles of ;90 patients each. For each of the four time
points, logistic regression analysis was performed, and
patients in the first quintile (,2.8 mg/liter CRP) served as
the control group (27,28). Receiver-operating characteristic
curve analysis over the dynamic range of the CRP assay was
used to identify the threshold level for CRP providing the
highest predictive value for risk stratifying patients with
unstable angina. Further, reverse stepwise logistic regression
analysis, including the variables TnT .0.1 mg/liter, CRP
.10 mg/liter, ECG findings and baseline characteristics,
identified independent predictors of cardiac risk. All anal-
yses were accomplished with SPSS 8.0.1 (SPSS Inc., Chi-
cago, Illinois) or StatXact-3 (Cytel Software Corp., Cam-
bridge, Massachusetts) software.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAPTURE 5 Chimeric c7E3 AntiPlatelet Therapy in
Unstable angina REfractory to standard
treatment trial
CI 5 confidence interval
CK 5 creatine kinase
CRP 5 C-reactive protein
FRISC 5 FRagmin during InStability in Coronary
artery disease trial
MI 5 myocardial infarction
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
TnT 5 troponin T
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RESULTS
Because we have previously shown that patients with ele-
vated TnT concentrations have outstanding benefit from
additional treatment with abciximab (13), patients receiving
abciximab had to be excluded from the main analysis.
Furthermore, a subset of 100 patients of the 547 patients
enrolled in the CAPTURE placebo group experienced MI
within 14 days (6.5 6 3.2 days) before enrollment. Because
elevated TnT levels in these 100 patients do not necessarily
reflect acute minor myocardial damage, data from this
subset were also not included in the main analysis. Thus, the
total number in our study was 447, with a total of 13 deaths
and 47 MIs during six-month follow-up (total event rate
13.4%).
TnT. For 30% of the patients (n 5 134), TnT was above
the diagnostic threshold level of 0.1 mg/liter. Baseline
characteristics, according to the TnT status, are depicted in
Table 1, with no significant differences between the groups.
Figure 1A shows the clinical outcomes of patients during
the first 72 h after randomization according to TnT status.
Notwithstanding identical treatment regimens, cardiac risk
(mortality, MI) was higher in TnT-positive patients during
both the first 24 h before PTCA (6.6% vs. 0.7%; p , 0.001)
and, especially, within first 72 h including the coronary
intervention (17.4% vs. 4.2%; p , 0.001). This absolute
difference in cardiac risk (D13.2%) increased only slightly
during the 30-day follow-up period (D14.7%; 19.6% vs.
4.9%; p , 0.001); this absolute difference was sustained
during the six-month follow-up period (D14.5%; 23.9% vs.
9.4%; p , 0.001).
Within the first 24 h before the planned coronary
intervention, 44.8% of the TnT-positive patients had at
least one episode of recurrent angina pectoris (mean 2.1
episodes). In contrast, symptoms recurred at least once for
only 16.9% of TnT-negative patients (p , 0.001; mean 1.2
episodes; p 5 0.004). Premature coronary revascularization
before scheduled PTCA was necessary for 6.7% of the
TnT-positive patients as compared with only 0.6% of the
TnT-negative patients (p 5 0.002). Further, for TnT-
positive patients, the rate of urgent coronary reinterventions
(PTCA, CABG) remained higher during the 30-day
follow-up period (11.2% vs. 3.8%; p 5 0.006), whereas
repeat nonurgent coronary revascularization (PTCA,
CABG) did not significantly differ between TnT-positive
and TnT-negative patients (3.0% vs. 4.5%; p 5 0.49).
CRP. INTERACTION BETWEEN CRP LEVEL AND CARDIAC
RISK. Patients were stratified into quintiles according to
their measured CRP levels: CRP-1) ,2.8 mg/liter (n 5
83); CRP-2) 2.9 to 5.3 mg/liter (n 5 85); CRP-3) 5.4 to 9.0
mg/liter (n 5 94); CRP-4) 10.0 to 22.6 mg/liter (n 5 98);
and CRP-5) .22.6 mg/liter (n 5 87). The CRP concen-
tration did not correlate with measured TnT levels (r2 5
0.12). A significantly higher mean level of TnT was docu-
mented for the fifth CRP quintile only (p , 0.01). Like-
wise, the proportion of patients with a positive TnT test
result (.0.1 mg/liter) was significantly higher only for the
highest CRP quintile (p , 0.01).
For the first 24- and 72-h periods, mortality and the
incidence of MI, respectively, for the second to fifth quintile
were not increased as compared with the first quintile (Fig.
2). However, patients in the forth and fifth quintiles (CRP
.10.0 mg/liter) had significantly higher event rates at
30-day and six-month follow-up, as compared with patients
in the first quintile. For the end point mortality at six-month
follow-up, in each of the first three quintiles, one patient
died, whereas in the fourth and fifth quintiles, four and six
patients, respectively, died. Receiver operating characteristic
curve analysis confirmed a threshold level of 10 mg/liter of
CRP for maximized predictive value.
STRATIFICATION ACCORDING TO CRP STATUS. In respect
to the aforementioned findings, the patient sample was
dichotomized according to this calculated threshold level.
We identified 185 patients (47%) with CRP .10 mg/liter
(CRP-positive) and 262 patients with CRP ,10 mg/liter
(CRP-negative). As Table 2 shows, there are no significant
Table 1. Baseline Characteristics According to Troponin
T Status
TnT-
Positive
Patients
(n 5 134)
TnT-
Negative
Patients
(n 5 313)
Male gender 66.7% 73.7%
Age (yrs) 62.7 6 10.5 60.9 6 10.2
History of
Angina .4 weeks 53.8% 57.3%
MI 14 to 30 days 2.2% 3.3%
MI .30 days 15.6% 22.7%
PTCA 15.1% 18.6%
CABG 3.8% 3.3%
Risk factors
Diabetes 11.3% 9.7%
Hypertension 36% 37.1%
Current smokers 40.8% 41.8%
Medication before enrollment
Aspirin 97.3% 98.3%
IV heparin 97.8% 99.5%
IV nitrates 98.4% 100%
Beta-blockers 62.9% 63.2%
Calcium antagonists 51.1% 57.9%
Medication after enrollment
Aspirin 97.3% 97.5%
Ticlopidine 2.7% 2.2%
IV heparin 97.3% 97.8%
IV nitrates 97.8% 98.3%
Beta-blockers 64% 60.7%
Calcium antagonists 50% 58.4%
Data are presented as percentage of patients or mean value 6 SD.
CABG 5 coronary artery bypass graft surgery; IV 5 intravenous; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty;
TnT 5 troponin T.
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differences in the baseline characteristics between the two
groups.
For CRP-negative patients, events (mortality and MI)
during the first 72 h were not significantly different from
those in patients with elevated CRP levels, neither during
24 h before the procedure (2.7% vs. 2.2%; p 5 1.00) nor after 72 h (including the coronary intervention) (10.3% vs.
8%; p 5 0.41) (Fig. 3). During the six-month follow-up
period, however, the event rate curves for CRP-positive and
CRP-negative patients continually diverged. There were
significant differences both after 30 days (14.1% vs. 7.6%;
p 5 0.03) and especially at six months (18.9% vs. 9.5%; p 5
0.003). This elevated risk in CRP-positive patients was
related to both a higher incidence of MI (13.5% vs. 8.4%;
p 5 0.16) for this subgroup and a significantly higher
mortality rate (5.4% vs. 1.1%; p 5 0.005).
Within the first 24 h before the planned coronary
intervention, 25.9% of the CRP-positive patients had at
least one episode of recurrent angina pectoris (mean 1.5
episodes). Symptoms recurred at least once in 24.8% of the
CRP-negative patients (p 5 0.92; mean 1.7 episodes; p 5
0.74). Likewise, the rate of urgent coronary reinterventions
(PTCA, CABG) was not elevated in CRP-positive patients
both before planned PTCA (3.1% vs. 1.6%; p 5 0.61) and
during the first 72 h including the coronary intervention
(5.9% vs. 3.1%; p 5 0.46). A trend toward a higher rate of
urgent interventions was observed in the CRP-positive
group only at 30-day follow-up (9.2% vs. 3.8%; p 5 0.08).
Further, repeat nonurgent coronary interventions (PTCA,
Figure 1. Event rates (mortality and MI) according to the patients’
TnT status during first 72 h (top panel) and after six months of
follow-up (bottom panel).
Figure 2. Event rates observed for the CRP quintiles according to
the four investigated periods after randomization.
Table 2. Baseline Characteristics According to C-Reactive
Protein Status
CRP-
Negative
Patients
(n 5 185)
CRP-
Positive
Patients
(n 5 262)
Male gender 73.9% 69%
Age (years) 59.8 6 10.8 63.1 6 10.3
History of
Angina .4 weeks 58.8% 53.8%
MI 14 to 30 days 3.5% 2.4%
MI .30 days 19.5% 21%
PTCA 19.1% 15.9%
CABG 3.5% 3.4%
Risk factors
Diabetes 12.1% 8.6%
Hypertension 39.3% 34.5%
Current smokers 40.9% 42.1%
Medication before enrollment
Aspirin 98.1% 97.9%
IV heparin 99.2% 98.6%
IV nitrates 98.8% 99.7%
Beta-blockers 65% 61.4%
Calcium antagonists 56% 55.2%
Medication after enrollment
Aspirin 97.7% 97.2%
Ticlopidine 2.3% 2.4%
IV heparin 97.7% 97.6%
IV nitrates 98.1% 98.3%
Beta-blockers 61.9% 61.7%
Calcium antagonists 54.9% 56.2%
Data are presented as percentage of patients or mean value 6 SD.
CRP 5 C-reactive protein; other abbreviations as in Table 1.
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CABG) during the six month follow-up period were sig-
nificantly more frequent in CRP-positive patients (7% vs.
2.3%; p 5 0.03).
PREDICTIVE VALUE OF CRP LEVEL AT DISCHARGE. A sec-
ond blood sample drawn before discharge (7.2 6 4.5 days
after randomization) was available for 402 (90%) of the 447
patients included in this study. Baseline CRP levels of
17.1 6 25.6 mg/liter increased until hospital discharge to a
mean value of 26.1 6 32.9 mg/liter (p , 0.001). The CRP
level was above the threshold level of 10.0 mg/liter for 265
patients (66%). For these CRP-positive patients, the inci-
dence of mortality and MI did not differ from that in
patients with CRP concentrations below this threshold
level. This was observed at 30 days (7.2% vs. 7.3%; p 5
1.00) and also at six months (11.7% vs. 9.5%; p 5 0.61).
There were also no significant differences of recurrent
instability requiring an urgent coronary intervention be-
tween CRP-positive and CRP-negative patients during the
30-day follow-up period (4.9% vs. 6.6%; p 5 0.44).
MULTIVARIATE ANALYSIS OF PREDICTIVE VALUES. Step-
wise backward regression analysis was used to identify
variables of independent predictive value for six-month
outcome (mortality and MI). Only TnT (p , 0.001), CRP
(p 5 0.01), age .65 years (p 5 0.02) and a history of MI
were independent predictors of an adverse clinical outcome
(Table 3). The inclusion of CK, MB fraction .5 mg/liter
and ECG findings such as ST segment depression and T
wave inversion or cardiac risk factors did not improve the fit
of the statistical model. When both clinical and ECG
findings were forced into the model first, the insertion of
both TnT and CRP significantly reduced the deviance of
the regression model. The likelihood ratio statistic was 5.31
after inclusion of clinical findings (p 5 0.023) and 18.38
after inclusion of both CRP and TnT (p , 0.001). After
inclusion of TnT and CRP, however, clinical and ECG
findings did not provide significant predictive value any-
more, and consequently were dropped from the model.
Patients with elevation of both TnT and CRP had the
highest incidence of mortality (5.3%), as measured at
six-month follow-up. For the TnT-negative group, the
determination of CRP identified a subgroup of patients
with increased mortality (2.1%). No deaths were docu-
mented during the six-month follow-up period in those
patients with all negative tests for both TnT and CRP (n 5
202) (Fig. 4).
EFFICACY OF TREATMENT WITH ABCIXIMAB ACCORDING
TO THE CRP STATUS. For this analysis, we examined data
from both the placebo (n 5 447) and abciximab (n 5 433)
groups of the CAPTURE trial participants. Regression
analysis, including a term of interaction, indicated no
significant correlation between CRP level and benefit of
treatment with abciximab. The treatment benefit was con-
sistent throughout all concentration levels for any chosen
threshold level and for all four time periods. At 30-day
follow-up, no significant differences were observed between
benefit of treatment with abciximab in patients with CRP
levels .10 mg/liter (odds ratio [OR] 0.52, 95% confidence
interval [CI] 0.21 to 0.92; p 5 0.011) and patients with
CRP levels ,10 mg/liter (OR 0.56, 95% CI 0.18 to 0.97;
p 5 0.008). At six-month follow-up, the benefit of abcix-
imab was not statistically significant for either group of
patients; for the samples with CRP levels .10 mg/liter, the
OR was 0.72 (95% CI 0.34 to 1.32; p 5 0.21) and for
Figure 3. Event rates (mortality and MI) according to the patients’
CRP status during first 72 h (top panel) and after six months of
follow-up (bottom panel).
Table 3. Results of Multivariate Analysis
Variable OR 95% CI
p
Value
Gender 0.91 0.65–1.49 0.59
Age .65 yrs 1.79 1.12–4.26 0.02
Diabetes mellitus 1.15 0.84–1.46 0.64
Hypercholesterolemia 0.89 0.71–1.16 0.65
Hypertension 0.99 0.85–1.06 0.99
History of angina 0.94 0.67–1.52 0.74
History of MI 0.89 0.72–1.25 0.66
History of PTCA 0.73 0.58–1.13 0.53
History of CABG 1.16 0.91–1.24 0.65
ST segment depression 1.21 0.86–1.98 0.21
T wave inversion 0.84 0.65–1.05 0.14
TnT .0.1 mg/liter 2.64 1.64–15.27 ,0.001
CRP .10.0 mg/liter 1.97 1.21–3.59 0.01
CK-MB .5.0 mg/liter 1.34 0.86–2.69 0.34
CI 5 confidence interval; CK-MB 5 creatine kinase, MB fraction; CRP 5
C-reactive protein; OR 5 odds ratio; other abbreviations as in Table 1.
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patients with normal CRP values, the OR was 0.67 (95% CI
0.46 to 1.06; p 5 0.13).
PREDICTIVE VALUE OF CRP FOR THE ENTIRE STUDY GROUP.
Because no interaction was observed between CRP values
and benefit of treatment with abciximab, the predictive
value of CRP was also investigated for the entire
CAPTURE study population, including all 1,081 patients
with an available baseline serum sample. A total of 23
deaths and 89 acute MIs were documented, resulting in a
total event rate of 10.4% at six month follow-up. For the
first 72 h, as already seen for the substudy group, CRP-
positive patients (n 5 516) did not have a higher event rate,
as compared with CRP-negative patients (n 5 565), neither
during the 24 h before the procedure (1.7% vs. 1.2%; p 5
0.72) nor after 72 h (including the coronary intervention)
(6.4% vs. 5.1%; p 5 0.56). During the six-month follow-up
period, however, event rates were significantly higher for
CRP-positive patients both at 30 days (8.1% vs. 5.3%; p 5
0.04) and at six months (14.9% vs. 6.2%; p , 0.001). This
elevated risk for patients with CRP levels .10 mg/liter was
driven by both a higher incidence for MI (OR 1.92, p 5
0.04) for this subgroup and, in particular, a significantly
higher mortality (OR 3.62, p , 0.001).
DISCUSSION
Consistent with previous studies (5–13), our results show
that patients with refractory unstable angina and minor
myocardial damage, evidenced by elevated TnT, are at
highest cardiac risk. Such risk was particularly marked
during the first 72 h after randomization and primarily
associated with evidence of MI after the percutaneous
coronary intervention. In contrast, CRP did not serve as a
significant predictor for such immediate risk. During the
first 72 h after randomization, including the coronary
intervention, cardiac risk in CRP-positive patients did not
differ significantly from that in CRP-negative patients.
However, for the six-month follow-up period, this study
confirms a strong and independent prognostic value for this
inflammatory marker. Elevation of CRP in patients with
refractory unstable angina differentiated TnT-negative pa-
tients with increased cardiac risk.
TnT. Cardiac TnT is a strong predictor for elevated
cardiac risk within the first days after the onset of symp-
toms. In the CAPTURE trial, in addition to the allocated
treatment (abciximab vs. placebo), all patients were identi-
cally treated with aspirin, intravenous heparin and nitrates
before their scheduled coronary interventions (Table 1)
(23). Despite such maximized treatment, there were signif-
icantly more cardiac complications occurring in patients
with a positive TnT test, both during the first 24 h before
the coronary intervention (6.6% vs. 0.7%; p , 0.001) and, in
particular, in association with PTCA (17.4% vs. 4.2%; p ,
0.001). Likewise, recurrence of symptoms (45% vs. 17%;
p , 0.001) and, consequently, recurrent instability with the
necessity for a premature coronary intervention before the
scheduled intervention were more frequent in the TnT-
positive group than in the TnT-negative group (6.7% vs.
0.7%; p , 0.001).
Such high risk patients should be given the highest
priority for transfer to a tertiary care center or to a
catheterization laboratory. However, these striking differ-
ences, despite aspirin and intravenous heparin therapy,
emphasize the necessity for a new and more effective
therapeutic strategy for such high risk patients. Increasing
evidence suggests that TnT elevation in patients with
unstable angina must be understood as a surrogate marker
for friable thrombus formation and complex lesion charac-
teristics (29,30). Accordingly, more potent platelet blockade
appears to be a reasonable approach. The glycoprotein
IIb/IIIa antagonist abciximab was particularly effective in
the treatment of TnT-positive patients in the CAPTURE
trial, with an 82% reduction of primary end points (mortal-
ity and MI) during the first 72 h after randomization (OR
0.18, p , 0.001) (13). In contrast, TnT-negative patients
were less symptomatic and at lower cardiac risk before and
in association with the coronary intervention. There were no
significant benefits of treatment with abciximab docu-
mented during the first 72-h period (OR 1.07, p 5 0.37).
After this 72 h after randomization, there were no signifi-
cant differences in cardiac risk between TnT-positive and
TnT-negative patients (6.5% vs. 5.2%; p 5 0.47)—a finding
that was independent of treatment. Troponin T, a marker of
acute risk in patients with unstable angina, identifies those
patients with the greatest benefit from abciximab.
C-reactive protein. There have been several recent studies
regarding elevated levels of CRP in patients with unstable
angina (16,17–19). They found that CRP in patients with
unstable angina was predictive of adverse clinical outcomes.
Because the present study embraced a large high risk patient
group, we expected CRP to be a significant predictor of
increased cardiac risk. However, in our work, the predictive
value of CRP was not correlated with increased cardiac risk
during the first 72 h; rather, it was associated with a higher
incidence of cardiac events during the six-month follow-up
Figure 4. Predictive value for the end point of mortality during the
6-month follow-up period according to both TnT and CRP status.
Open bar 5 CRP-negative patients; solid bars 5 CRP-positive
patients.
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period. Event rate curves according to the CRP status
diverged only slightly during the immediate phase of the
coronary syndrome, with no significant differences at 72 h
(10.3% vs. 8%; p 5 0.41). However, the curves diverged
during the six month follow-up period, resulting in highly
significant differences (18.9% vs. 9.5%; p 5 0.003). Because
no interaction between treatment with abciximab and CRP
level was documented, we were able to confirm these
findings by investigating the predictive value of CRP for the
entire study population (n 5 1,091), which cannot be done
for TnT due to the significant interaction between abcix-
imab and TnT level.
Thus, CRP levels might be of less predictive value for the
acute risk of patients with unstable angina than has been
suggested from previous experiences in, however, limited
patient groups. The larger FRagmin during InStability in
Coronary artery disease (FRISC) trial documented no
differences in cardiac risk (mortality and MI) for their
patient groups categorized in tertiales according to the
patients’ CRP level (20). This finding was consistent for
both the first hospital period and the six-month follow-up
period. The CRP tertiales differed only slightly in the
respective measures of the end point mortality at six-month
follow-up. However, it should be noted that for the sub-
group analysis of the FRISC trial, those patients treated
with low molecular weight heparin for five weeks and those
patients receiving placebo were included, possibly biasing
the analyses. Further, the total event rate in FRISC was
markedly low as compared with that of the CAPTURE
trials. In the Thrombolysis in Myocardial Infarction (TIMI)
11A substudy of patients with unstable angina or non–Q
wave MI, elevated CRP levels at presentation (threshold
level 15.5 mg/liter) were associated with increased 14-day
mortality (19). This was observed even in patients with a
negative TnT rapid test. These findings are fully consistent
with our CAPTURE results. Our analysis shows that
despite the negative TnT test result, the group of patients
with elevated CRP levels had particularly high mortality,
both at 30 days and six months (5.4% vs. 1.1%; p 5 0.002).
All CRP-positive patients died of cardiac causes, mainly
MI.
Discharge CRP values were not predictive of either the
composite end point of mortality/MI or the end point of
restenosis at six-month follow-up. This might be due to the
fact that all patients underwent a coronary intervention, and
CRP levels consequently increased from baseline to hospital
discharge.
Therapeutic consequences for high risk patients. In con-
trast to the findings with TnT (13), the efficacy of treatment
with abciximab in the CAPTURE trial did not differ
between patients stratified according to CRP status. Studies
with platelet glycoprotein IIb/IIIa receptor blockers have
unequivocally shown that after the unstable phase of the
acute coronary syndrome, cardiac events continue to occur
for both the treatment and placebo groups at comparable
frequencies (23,31–33). In such studies, there was no
incremental benefit of glycoprotein IIb/IIIa receptor block-
ade in preventing later events. Because CRP values did not
predict the instability of patients during the first days after
the onset of symptoms, it was not unexpected that CRP was
not predictive of the efficacy of treatment with abciximab.
However, the observed event rate after stabilization of the
patients for the period between four-day and six-month
follow-up is of clinical significance. In the CAPTURE trial,
event rates during first 72-h period were 4.2% for the
abciximab group and 8.3% for the placebo group (p 5
0.003). Between day four and six-month follow-up, how-
ever, the event rate was ;5% and was independent of
randomized treatment. In this study, CRP was identified as
a marker of increased risk after this first 72-h period. All
patients with positive CRP baseline values, regardless of
treatment group, were at increased risk during the follow-up
period (8.7% event rate for the placebo group and 8.3% for
the abciximab group), whereas patients with normal CRP
values were at low risk (1.5% for the placebo group and 2.6%
for the abciximab group). Further, the incidence of symp-
tomatic coronary restenosis during the six-month follow-up
period was not related to the patients’ TnT status (3% vs.
4.5%; p 5 0.49), but was significantly correlated to the
patients’ CRP status (7% vs. 2.3%; p 5 0.03).
These findings support the hypothesis that local or
systemic inflammation plays an important role in the pro-
gression of atherosclerosis. The absolute difference in car-
diac risk of ;7% between CRP-positive and CRP-negative
patients may be useful in clinical practice to guide more
aggressive and uncompromising medical treatment. We
speculate that these patients, in particular, would benefit
from treatment with cholesterol-synthesizing enzymes in-
hibitors (34).
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